Efficacy of Remote Monitoring in Patients Treated for Moderate to Major Depressive Episodes (EC-102)

Resilience

Status

Enrolling

Conditions

Mood Disorder (Depressive Episodes)

Treatments

Device: Edra PRO

Study type

Interventional

Funder types

Industry

Identifiers

NCT07087353

2025-A01782-47 (Other Identifier)

EC-102

Details and patient eligibility

About

Mood disorders like depression and bipolar disorder are widespread and cause serious psychological, cognitive, and social impairments, with a high burden on healthcare systems. Edra PRO is a digital medical device developed to support clinical decision-making and remotely monitor symptoms in psychiatric patients. The EC-102 randomized controlled trial will evaluate its impact compared to usual care on symptoms, quality of life, healthcare costs, comorbidities, and user adherence and satisfaction.

Full description

Mood disorders such as depression and bipolar disorder affect a large portion of the global population and cause significant psychological, cognitive, and functional impairments, along with high healthcare costs. Despite available treatments, sustained remission is hard to achieve, and many patients experience persistent symptoms and treatment side effects. Continuous remote monitoring could improve care and outcomes. Edra PRO is a digital medical device designed for remote symptom tracking and clinical decision support in psychiatry. The EC-102 randomized controlled trial will assess the impact of Edra PRO versus usual care on symptoms, quality of life, healthcare costs, comorbidities, and user satisfaction and adherence.

Enrollment

594 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adults (≥18 years old) meeting ICD-11 criteria for a moderate to severe major depressive episode
Access to a personal smartphone and an internet connection, and cognitively able to use it independently

Exclusion criteria

Pregnant women
Individuals under legal guardianship or conservatorship
Ongoing alcohol or drug abuse considered likely to interfere with study participation, as judged by the investigator
Psychiatric or physical comorbidities (e.g., severe neurological or cardiovascular conditions) considered likely to interfere with participation or study results, at the discretion of the Principal Investigator